Advances in atopic dermatitis and urticarial in 2016

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:140

Article

Honda, Tetsuya¹  Nomura, Takashi¹  Kabashima, Kenji^1,2,3 

[1] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan

[2] ASTAR, Singapore Immunol Network SIgN, Biopolis, Singapore

[3] ASTAR, IMB, Biopolis, Singapore

关键词: Atopic dermatitis;    chronic spontaneous urticaria;    biologics;    microbiome;    biomarker;    transcriptome;   

DOI  :  10.1016/j.jaci.2017.06.005

来源: Elsevier

【 摘 要 】

This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis with human samples revealed different immune profiles between childhood and adult AD. Phase III clinical trials of dupilumab, an anti-IL-4 receptor a antibody, in the treatment of AD have successfully finished, and dupilumab will appear in clinical practice as the first biologic for AD in 2017. In addition, a novel biologic that targets IL-31 shows promising results in a phase II trial. As for the skin microbiome study, novel insights into the mechanisms of microbial dysbiosis, such as colonization of Staphylococcus aureus, a common feature of AD, were proposed. Regarding CSU, autoreactive CD4(+) T cells that react to Fc epsilon RI were discovered, which might contribute to the development of CSU. These findings provide new insights into the pathogenesis of AD and CSU and will lead to more specific and personalized treatments.

【 授权许可】

Free